More Promising Tirzepatide Data; Continuous Glucose Monitoring Wins in Diabetes

News

The investigational dual GIP and GLP-1 receptor agonist tirzepatide significantly reduced HbA1c levels and induced weight loss in patients with type 2 diabetes compared with insulin glargine in the SURPASS-4 trial, Eli Lilly announced.

A randomized trial of 175 adults with type 2 diabetes treated with basal insulin without prandial insulin found better glycemic control among those using continuous glucose monitoring. (JAMA)

In another study from JAMA looking at patients with type 1 and type 2 diabetes, real-time continuous glucose monitoring was tied to an average 0.4% lower HbA1c level and lower rates of hypoglycemia-related hospitalizations.

On a related note, new real-world data found that patients using the Medtronic MiniMed 780G system had an average overall time in range of 76.2% and an overnight time in range of 83%.

The FDA granted fast-track designation to encaleret, the investigational treatment for autosomal dominant hypocalcemia type 1, a rare, genetic form of hypoparathyroidism, BridgeBio Pharma announced.

The FDA and Federal Trade Commission issued warning letters to five companies for illegally hocking dietary supplements claiming to cure infertility.

Eating at least two servings of fruit each day was tied to a 36% lower chance of developing type 2 diabetes, according to a new study of nearly 7,700 adults. “We did not see the same patterns for fruit juice. These findings indicate that a healthy diet and lifestyle which includes the consumption of whole fruits is a great strategy to lower your diabetes risk,” said study author Nicola Bondonno, PhD, of Edith Cowan University’s Institute for Nutrition Research in Perth, Australia. (Journal of Clinical Endocrinology & Metabolism)

By 2030, long-acting growth hormones are expected to make up 90% of the growth hormone deficiency market. (GlobalData)

Women who have undergone a bilateral oophorectomy prior to menopause saw an increased risk for severe carpal tunnel syndrome, which not even estrogen therapy could mitigate. (Menopause)

  • author['full_name']

    Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry, and dermatology news. Based out of the New York City office, she’s worked at the company for nearly five years.

Leave a Reply

Your email address will not be published. Required fields are marked *